Healthcare
Live Price
Offline$11.90
-7.82% today
1Y Change
+686.27%
Window
Jun 23, 2025 β Jun 8, 2026
Coverage: 241 bars Β· Jun 23, 2025 β Jun 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Q32 Bio Inc. (QTTB) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $11.90 and up 686.3% across the available one-year price window (Jun 23, 2025 β Jun 8, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +147.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +147.3%, free cash flow +64.3% with operating margin 31.5% and ROIC 29.8%. Valuation is more restrained than many high-expectation growth names at P/E 2.1 and price/sales 1.2. Stock Foundry combines QTTB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
QTTB
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
QTTB Max Drawdown
-51.14%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Uses the longest available daily history for QTTB and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$34.0M
+410.8% YoY
FY Net Income
-$95.8M
-123.7% YoY
Free Cash Flow
-$112.1M
-734.3% YoY
Revenue Growth
+0.0%
EPS Growth
+147.3%
Gross Margin
99.7%
Net Margin
55.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 54M | 0 | -7M | 7M | 34M |
| Gross Profit | 53M | -487K | -7M | 7M | 24M |
| Operating Income | 17M | -66M | -48M | -39M | -96M |
| EBITDA | 17M | -45M | -48M | -39M | -86M |
| Net Income | 30M | -48M | -54M | -43M | -96M |
| EPS (Diluted) | β | β | β | β | β |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 48M | 78M | 26M | 44M | 108M |
| Total Assets | 62M | 92M | 47M | 62M | 212M |
| Total Liabilities | 20M | 87M | 230M | 192M | 42M |
| Shareholder Equity | 42M | 6M | -183M | 178M | 170M |
| Total Debt | 15M | 19M | 51M | 45M | 24M |
| Net Debt | -33M | -59M | 25M | 838K | -84M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
110M
-901.7% YoY
Capital Expenditures
2M
+3.6% YoY
Free Cash Flow
112M
-734.3% YoY
Key ratios
Gross Margin
99.7%
Operating Margin
31.5%
Net Margin
55.5%
ROE
1630.2%
Debt / Equity
0.27x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.